{"abstract":"The National Institute on Aging, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Paz Pharmaceuticals, LLC of the State of Delaware.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2020/06/22/2020-13316.html","cfr_references":[],"citation":"85 FR 37464","comment_url":null,"comments_close_on":"2020-07-07","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 7, 2020 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2020-13316","effective_on":null,"end_page":37466,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2020/06/22/2020-13316.xml","html_url":"https://www.federalregister.gov/documents/2020/06/22/2020-13316/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-fenoterol-and","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2020-13316?publication_date=2020-06-22","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2020-06-22/2020-13316/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":210,"last_updated":"2026-09-22 20:15:08 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2020-06-22/pdf/2020-13316.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2020-13316.pdf?1592570724","publication_date":"2020-06-22","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2020/06/22/2020-13316.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T05:17:37Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":37464,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the Treatment of Cancer","toc_doc":"Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the Treatment of Cancer","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":85}